| Feature Story: |
Over 1.8 Million Stents Implanted per Year in the U.S. |
There are over 1.8 million stents implanted per year in the United States. Approximately 965,000 of these can be attributed to the implantation of coronary stents, whereas the remaining, pertain to peripheral vascular stents.
Coronary stents are implanted through percutaneous coronary intervention (PCI) procedures. Unit sales growth for the total coronary stent market is highly correlated with the annual PCI procedure volume, and any significant changes will exhibit a direct effect on sales volume.
In the past, over-stenting was scrutinized heavily, with numerous studies estimating that approximately 30% of coronary stenting procedures performed are unnecessary. As a result...
Click here to read more |
|
|
 According to a new study by iData Research, approximately 340,000 CABG procedures per year are performed in the United States. A CABG (Coronary Artery Bypass Grafting) procedure is a common cardiac surgery where a harvested vein is grafted onto the heart to bypass blocked arteries.
This procedure can be done on-pump (ONCAB), where a cardioplegic solution is used to stop the heart and the patient’s circulatory system is temporarily maintained through the use of a cardiopulmonary bypass (CPB), or off-pump (OPCAB), also known as...
read more}
|
|
 QT Vascular Ltd., (“QT Vascular“, and with its subsidiaries, the “Company“), announced that it has entered into an asset purchase and option agreement (the “APOA“) with Teleflex Life Sciences Unlimited Company and Teleflex Incorporated (“Teleflex“). Under the APOA, Teleflex will acquire the non-drug coated product line and licenses with respect to intellectual property related to the Company’s non-drug coated coronary products (including Chocolate XD® and Glider™). The APOA also provides Teleflex with an option (the “Option“) to purchase the drug coated coronary balloon catheter, referred to as...
read more}
|
|
 Baxter International Inc., a leader in innovative technology for medication delivery, announced the U.S. Food and Drug Administration (FDA) clearance of the Spectrum IQ Infusion System with Dose IQ Safety Software. The Spectrum IQ system is the first-of-its-kind designed specifically for bi-directional electronic medical records (EMR) integration with new exclusive features to help ensure the correct medications and fluids are delivered to the patient. The Spectrum IQ system also builds upon proven Spectrum infusion pump technology and Baxter’s comprehensive approach to patient safety to help make ...
read more}
|
|
 Medtronic announces results through 12-months from the Post-Approval Registry (PAR) for the Medtronic Micra(TM) Transcatheter Pacing System (TPS), reinforcing the high implant success rate and low complication rate seen since its U.S. approval two years ago.
The smallest pacemaker in the world, Micra TPS is the only leadless pacemaker approved in the U.S. New data from the PAR study showed Micra TPS in clinical practice had an implant success rate of 99.1 percent. The PAR study also showed a low major complication rate (2.7 percent) through 12 months post-implant (95 percent CI: 2.0 percent – 3.6 percent), with a 63 percent lower...
read more}
|
|
|
|
|
|
|
|
